Tudor Investment Corp
NRIX icon

Tudor Investment Corp’s Nurix Therapeutics NRIX Stock Holding History

Tudor Investment Corp’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,760
Closed -$659K – 4084
2025
Q4 		$659K Sell
34,760
-3,183
-8% -$45.7K ﹤0.01% 2553
2025
Q3 		$351K Buy
+37,943
New +$394K ﹤0.01% 2882
2024
Q4 		– Sell
-22,259
Closed -$500K – 3360
2024
Q3 		$500K Buy
22,259
+211
+1% +$4.78K ﹤0.01% 2036
2024
Q2 		$460K Buy
+22,048
New +$343K ﹤0.01% 1841
2024
Q1 		– Sell
-22,071
Closed -$228K – 2609
2023
Q4 		$228K Buy
+22,071
New +$151K ﹤0.01% 2151
2023
Q3 		– Sell
-12,991
Closed -$130K – 2681
2023
Q2 		$130K Sell
12,991
-9,115
-41% -$93K ﹤0.01% 2279
2023
Q1 		$196K Sell
22,106
-56
-0.3% -$584 ﹤0.01% 2184
2022
Q4 		$243K Sell
22,162
-35
-0.2% -$422 ﹤0.01% 2033
2022
Q3 		$289K Buy
22,197
+1,848
+9% +$29.2K 0.01% 1817
2022
Q2 		$258K Sell
20,349
-2,200
-10% -$24.9K 0.01% 1665
2022
Q1 		$316K Sell
22,549
-2,300
-9% -$40.8K 0.01% 1524
2021
Q4 		$719K Buy
+24,849
New +$753K 0.01% 1215

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Tudor Investment Corp's NRIX Position: Q1 2026 in Review

Tudor Investment Corp sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 34,760 shares — an estimated $659K sold.

Tudor Investment Corp first reported a position in NRIX in Q4 2021 and held it in 12 quarters. The position peaked at $719K in Q4 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Tudor Investment Corp reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tudor Investment Corp sold 34,760 Nurix Therapeutics shares in Q1 2026, an estimated $659K.
  • Tudor Investment Corp first reported a position in Nurix Therapeutics in Q4 2021 and held it in 12 quarters.
  • Tudor Investment Corp's Nurix Therapeutics position peaked at $719K in Q4 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.